Financing ·
Surrozen raises $95.1M in second tranche private placement following FDA IND clearance
SRZNSurrozen, Inc.
Surrozen completed the second and final closing of its March 2025 private placement, generating approximately $95.1 million in gross proceeds. The transaction was contingent upon FDA clearance of the Investigational New Drug application for SZN-8141, which occurred on October 2, 2026. The company issued 5,741,605 shares of common stock, pre-funded warrants to purchase 2,456,500 shares, and Series E common stock warrants to purchase 4,099,052 shares at a price of $11.60 per share. Proceeds will strengthen the balance sheet and provide cash runway into 2029 to advance clinical development of SZN-8141 and SZN-8143. Surrozen is a biotechnology company pioneering Wnt-based therapeutics for sight-threatening ophthalmic conditions.